Nucleotide-binding oligomerization domain 2 and toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan

Arthritis and Rheumatism

Volumn 62, Issue 4, 2010, Pages 1051-1059

  Rosenzweig, Holly L ^a   Jann, Monica J ^b   Vance, Emily E ^a   Planck, Stephen R ^a   Rosenbaum, James T ^a   Davey, Michael P ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; MURAMYL DIPEPTIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; FLUORESCENCE IMAGING; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; GENOTYPE; JOINTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NOD2 SIGNALING ADAPTOR PROTEIN; PEPTIDOGLYCAN; RATS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 77950535933     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27335     Document Type: Article

References (31)

1. Geddes K, Magalhaes JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov 2009; 8:465-479
2. Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009;4:365-398
3. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19-20.
4. Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985;107:689-693
5. Jabs DA, Houk JL, Bias WB, Arnett FC. Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 1985;78: 801-804
6. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. (Pubitemid 32531408)
7. Tanabe T, Chamaillard M, Ogura Y, Zhu L, Qiu S, Masumoto J, et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 2004;23:1587-1597 (Pubitemid 38579519)
8. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869-8872 (Pubitemid 36800360)
9. Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, Philpott DJ, et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003;278:41702-41708 (Pubitemid 37310428)
10. Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 2007;178:2380-2386 (Pubitemid 46233437)
11. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, et al. CARD4/Nod1 mediates NF-κB and JNK activation by invasive Shigella flexneri. EMBO Rep 2001;2:736-742 (Pubitemid 32798718)
12. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002;416:194-199 (Pubitemid 34246479)
13. Pauleau AL, Murray PJ. Role of Nod2 in the response of macrophages to Toll-like receptor agonists. Mol Cell Biol 2003; 23:7531-7539
14. Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005;35:2459-2470 (Pubitemid 41179767)
15. Tada H, Aiba S, Shibata K, Ohteki T, Takada H. Synergistic effect of Nod1 and Nod2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 2005;73:7967-7976 (Pubitemid 41740282)
16. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusomoto S, Shibata K, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with a chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocyte cells in culture. Cell Microbiol 2005;7: 53-61.
17. Van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BM, Mengin-Lecreulx D, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 2005;35: 2471-2476 (Pubitemid 41179768)
18. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, Fuss IJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008;118:545-559
19. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5:800-808 (Pubitemid 39172973)
20. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006;25:473-485 (Pubitemid 44355006)
21. Rosenzweig HL, Jann MM, Glant T, Martin TM, Planck SR, van Eden W, et al. Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis. J Leukoc Biol 2009;85:711-718
22. Ospelt C, Brentano F, Jungel A, Rengel Y, Kolling C, Michel BA, et al. Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60:355-363
23. Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, Ferwerda G, Lebourhis L, Philpott DJ, et al. Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc Natl Acad Sci U S A 2008;105:9017-9022
24. Van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000;43:593-598 (Pubitemid 30394951)
25. Saha S, Qi J, Wang S, Wang M, Li X, Kim YG, et al. PGLYRP-2 and Nod2 are both required for peptidoglycan-induced arthritis and local inflammation. Cell Host Microbe 2009;5:137-150
26. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171: 6145-6153 (Pubitemid 37467237)
27. Wunder A, Tung CH, Muller-Ladner U, Weissleder R, Mahmood U. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum 2004;50:2459-2465
28. Zhou X, Gao XP, Fan J, Liu Q, Anwar KN, Frey RS, et al. LPS activation of Toll-like receptor 4 signals CD11b/CD18 expression in neutrophils. Am J Physiol Lung Cell Mol Physiol 2005;288: L655-62.
29. Davey MP, Martin TM, Planck SR, Lee J, Zamora D, Rosenbaum JT. Human endothelial cells express NOD2/CARD15 and increase IL-6 secretion in response to muramyl dipeptide. Microvasc Res 2006;71:103-107
30. Sugawara Y, Uehara A, Fujimoto Y, Kusumoto S, Fukase K, Shibata K, et al. Toll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res 2006;85:524-529
31. Yang S, Takahashi N, Yamashita T, Sato N, Takahashi M, Mogi M, et al. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 α, and TNF-α through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. J Immunol 2005;175:1956-1964